EBS - Siga Technologies receives approval from UK for tecovirimat
- United Kingdom has approved SIGA Technologies's ( NASDAQ: SIGA ) oral tecovirimat for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox in adults and children with a body weight of at least 13kg.
- Similar formulation of tecovirimat was approved by the U.S. Food and Drug Administration in 2018 and by Health Canada in late 2021 under the brand name TPOXX for the treatment of smallpox.
- In early 2022 SIGA also received market authorization for tecovirimat from the European Medicines Agency for the treatment of smallpox, monkeypox, cowpox, and complications from vaccinia infection.
- Vaccine developers for monkeypox: Bavarian Nordic ( OTCPK:BVNKF ) ( OTCPK:BVNRY ), Emergent BioSolutions ( EBS ), Chimerix ( CMRX ).
- Developers of monkeypox therapeutics: GeoVax Labs ( GOVX ), SIGA Technologies ( SIGA ) and Tonix Pharmaceuticals ( TNXP ).
- Developers of diagnostics for monkeypox: Co-Diagnostics ( CODX ), Roche ( OTCQX:RHHBY ) ( OTCQX:RHHBF ), Abbott Laboratories ( ABT ).
- Read: In a previous meeting last month, WHO’s Emergency Committee declined to issue the PHEIC designation for the current monkeypox outbreak.
- Shares of SIGA are up 5.1% premarket.
For further details see:
Siga Technologies receives approval from UK for tecovirimat